MediWound Ltd. (NASDAQ:MDWD) Stock Has Consensus Target Price of $33.00 According to Brokerages

Shares of MediWound Ltd. (NASDAQ:MDWD) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $33.00.

A number of analysts recently weighed in on MDWD shares. Weiss Ratings cut shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Alliance Global Partners restated a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday, August 14th. TD Cowen reiterated a “buy” rating on shares of MediWound in a research note on Thursday, September 24th. Finally, Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th.

Insider Transactions at MediWound

In other MediWound news, COO Shmuel Hess sold 3,958 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MediWound stock. Clal Insurance Enterprises Holdings Ltd grew its stake in MediWound Ltd. (NASDAQ:MDWD) by 22.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,000 shares of the biopharmaceutical company’s stock after purchasing an additional 13,196 shares during the period. Clal Insurance Enterprises Holdings Ltd owned approximately 0.55% of MediWound worth $1,311,000 at the end of the most recent reporting period. Institutional investors own 46.83% of the company’s stock.

MediWound Trading Down 2.9%

Shares of NASDAQ MDWD opened at $11.85 on Friday. The stock has a market cap of $152.27 million, a P/E ratio of -6.58 and a beta of 0.09. MediWound has a twelve month low of $11.84 and a twelve month high of $20.03. The stock has a 50 day moving average of $13.24 and a two-hundred day moving average of $14.66.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). The business had revenue of $3.09 million for the quarter, compared to analysts’ expectations of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. As a group, research analysts predict that MediWound will post -2.37 earnings per share for the current year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biotechnology company focused on developing and commercializing innovative therapies for complex wounds. The company’s products are designed to remove damaged tissue, support wound healing and address unmet needs in burn care and chronic wounds.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based enzymatic treatment used to remove eschar—the dead tissue that can form after severe thermal burns. NexoBrid has received regulatory approvals in multiple markets, including the United States, the European Union and Israel, and is marketed for use in the treatment of deep partial-thickness and full-thickness burns.

The company is also developing EscharEx, an investigational topical treatment intended to enzymatically debride chronic wounds, including venous leg ulcers.